Suggested Ontology for Pharmacogenomics (SO-Pharm) : Modular Construction and Preliminary Testing
Identifieur interne :
000342 ( PascalFrancis/Corpus );
précédent :
000341;
suivant :
000343
Suggested Ontology for Pharmacogenomics (SO-Pharm) : Modular Construction and Preliminary Testing
Auteurs : Adrien Coulet ;
Malika Smail-Tabbone ;
Amedeo Napoli ;
Marie-Dominique DevignesSource :
-
Lecture notes in computer science [ 0302-9743 ] ; 2006.
RBID : Pascal:08-0058235
Descripteurs français
- Pascal (Inist)
- Système réparti,
Internet,
Ontologie,
Découverte connaissance,
Fouille donnée,
Représentation connaissance,
Construction modulaire,
DNA,
Médicament,
Industrie pharmaceutique,
Génotype,
Base de connaissances,
Phénotype,
Validation,
..
English descriptors
- KwdEn :
- DNA,
Data mining,
Distributed system,
Drug,
Genotype,
Internet,
Knowledge base,
Knowledge discovery,
Knowledge representation,
Modular construction,
Ontology,
Pharmaceutical industry,
Phenotype,
Validation.
Abstract
Pharmacogenomics studies the involvement of interindividual variations of DNA sequence in different drug responses (especially adverse drug reactions). Knowledge Discovery in Databases (KDD) process is a means for discovering new pharmacogenomic knowledge in biological databases. However data complexity makes it necessary to guide the KDD process by representation of domain knowledge. Three domains at least are in concern: genotype, drug and phenotype. The approach described here aims at reusing whenever possible existing domain knowledge in order to build a modular formal representation of domain knowledge in pharmacogenomics. The resulting ontology is called SO-Pharm for Suggested Ontology for Pharmacogenomics. Various situations encountered during the construction process are analyzed and discussed. A preliminary validation is provided by representing with SO-Pharm concepts some well-known examples of pharmacogenomic knowledge.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
| A01 | 01 | 1 | | @0 0302-9743 |
|---|
| A05 | | | | @2 4277 |
|---|
| A08 | 01 | 1 | ENG | @1 Suggested Ontology for Pharmacogenomics (SO-Pharm) : Modular Construction and Preliminary Testing |
|---|
| A09 | 01 | 1 | ENG | @1 On the move to meaningful internet systems 2006. Part I-II : OTM 2006 workshops : OTM Confederated International Workshops and Posters, AWeSOMe, CAMS, COMINF, IS, KSinBIT, MIOS-CIAO, MONET, OnToContent, ORM, PerSys, OTM Academy Doctoral Consortium, RDDS, SWWS, and SeBGIS 2006, Montpellier, France, October 29 - November 3, 2006 : proceedings |
|---|
| A11 | 01 | 1 | | @1 COULET (Adrien) |
|---|
| A11 | 02 | 1 | | @1 SMAIL-TABBONE (Malika) |
|---|
| A11 | 03 | 1 | | @1 NAPOLI (Amedeo) |
|---|
| A11 | 04 | 1 | | @1 DEVIGNES (Marie-Dominique) |
|---|
| A14 | 01 | | | @1 KIKA Medical, 35 rue de Rambouillet @2 75012 Paris @3 FRA @Z 1 aut. |
|---|
| A14 | 02 | | | @1 LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239 @2 54506 Vandoeuvre-lès-Nancy @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. |
|---|
| A20 | | | | @1 648-657 |
|---|
| A21 | | | | @1 2006 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A26 | 01 | | | @0 3-540-48269-5 |
|---|
| A43 | 01 | | | @1 INIST @2 16343 @5 354000172814200850 |
|---|
| A44 | | | | @0 0000 @1 © 2008 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 17 ref. |
|---|
| A47 | 01 | 1 | | @0 08-0058235 |
|---|
| A60 | | | | @1 P @2 C |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Lecture notes in computer science |
|---|
| A66 | 01 | | | @0 DEU |
|---|
| A66 | 02 | | | @0 USA |
|---|
| C01 | 01 | | ENG | @0 Pharmacogenomics studies the involvement of interindividual variations of DNA sequence in different drug responses (especially adverse drug reactions). Knowledge Discovery in Databases (KDD) process is a means for discovering new pharmacogenomic knowledge in biological databases. However data complexity makes it necessary to guide the KDD process by representation of domain knowledge. Three domains at least are in concern: genotype, drug and phenotype. The approach described here aims at reusing whenever possible existing domain knowledge in order to build a modular formal representation of domain knowledge in pharmacogenomics. The resulting ontology is called SO-Pharm for Suggested Ontology for Pharmacogenomics. Various situations encountered during the construction process are analyzed and discussed. A preliminary validation is provided by representing with SO-Pharm concepts some well-known examples of pharmacogenomic knowledge. |
|---|
| C02 | 01 | X | | @0 001D02B07D |
|---|
| C02 | 02 | X | | @0 002B02A |
|---|
| C02 | 03 | X | | @0 001D02B07B |
|---|
| C02 | 04 | X | | @0 001D02C |
|---|
| C03 | 01 | X | FRE | @0 Système réparti @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Distributed system @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Sistema repartido @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Internet @5 02 |
|---|
| C03 | 02 | X | ENG | @0 Internet @5 02 |
|---|
| C03 | 02 | X | SPA | @0 Internet @5 02 |
|---|
| C03 | 03 | X | FRE | @0 Ontologie @5 06 |
|---|
| C03 | 03 | X | ENG | @0 Ontology @5 06 |
|---|
| C03 | 03 | X | SPA | @0 Ontología @5 06 |
|---|
| C03 | 04 | X | FRE | @0 Découverte connaissance @5 07 |
|---|
| C03 | 04 | X | ENG | @0 Knowledge discovery @5 07 |
|---|
| C03 | 04 | X | SPA | @0 Descubrimiento conocimiento @5 07 |
|---|
| C03 | 05 | X | FRE | @0 Fouille donnée @5 08 |
|---|
| C03 | 05 | X | ENG | @0 Data mining @5 08 |
|---|
| C03 | 05 | X | SPA | @0 Busca dato @5 08 |
|---|
| C03 | 06 | X | FRE | @0 Représentation connaissance @5 09 |
|---|
| C03 | 06 | X | ENG | @0 Knowledge representation @5 09 |
|---|
| C03 | 06 | X | SPA | @0 Representación conocimientos @5 09 |
|---|
| C03 | 07 | X | FRE | @0 Construction modulaire @5 18 |
|---|
| C03 | 07 | X | ENG | @0 Modular construction @5 18 |
|---|
| C03 | 07 | X | SPA | @0 Construcción modular @5 18 |
|---|
| C03 | 08 | X | FRE | @0 DNA @5 19 |
|---|
| C03 | 08 | X | ENG | @0 DNA @5 19 |
|---|
| C03 | 08 | X | SPA | @0 DNA @5 19 |
|---|
| C03 | 09 | X | FRE | @0 Médicament @5 20 |
|---|
| C03 | 09 | X | ENG | @0 Drug @5 20 |
|---|
| C03 | 09 | X | SPA | @0 Medicamento @5 20 |
|---|
| C03 | 10 | X | FRE | @0 Industrie pharmaceutique @5 21 |
|---|
| C03 | 10 | X | ENG | @0 Pharmaceutical industry @5 21 |
|---|
| C03 | 10 | X | SPA | @0 Industria farmacéutica @5 21 |
|---|
| C03 | 11 | X | FRE | @0 Génotype @5 22 |
|---|
| C03 | 11 | X | ENG | @0 Genotype @5 22 |
|---|
| C03 | 11 | X | SPA | @0 Genotipo @5 22 |
|---|
| C03 | 12 | X | FRE | @0 Base de connaissances @5 23 |
|---|
| C03 | 12 | X | ENG | @0 Knowledge base @5 23 |
|---|
| C03 | 12 | X | SPA | @0 Base conocimiento @5 23 |
|---|
| C03 | 13 | X | FRE | @0 Phénotype @5 24 |
|---|
| C03 | 13 | X | ENG | @0 Phenotype @5 24 |
|---|
| C03 | 13 | X | SPA | @0 Fenotipo @5 24 |
|---|
| C03 | 14 | X | FRE | @0 Validation @5 25 |
|---|
| C03 | 14 | X | ENG | @0 Validation @5 25 |
|---|
| C03 | 14 | X | SPA | @0 Validación @5 25 |
|---|
| C03 | 15 | X | FRE | @0 . @4 INC @5 82 |
|---|
| N21 | | | | @1 028 |
|---|
| N44 | 01 | | | @1 OTO |
|---|
| N82 | | | | @1 OTO |
|---|
|
|---|
| pR |
| A30 | 01 | 1 | ENG | @1 OTM Confederated International Workshops @3 Montpellier FRA @4 2006 |
|---|
|
|---|
Format Inist (serveur)
| NO : | PASCAL 08-0058235 INIST |
|---|
| ET : | Suggested Ontology for Pharmacogenomics (SO-Pharm) : Modular Construction and Preliminary Testing |
|---|
| AU : | COULET (Adrien); SMAIL-TABBONE (Malika); NAPOLI (Amedeo); DEVIGNES (Marie-Dominique) |
|---|
| AF : | KIKA Medical, 35 rue de Rambouillet/75012 Paris/France (1 aut.); LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239/54506 Vandoeuvre-lès-Nancy/France (1 aut., 2 aut., 3 aut., 4 aut.) |
|---|
| DT : | Publication en série; Congrès; Niveau analytique |
|---|
| SO : | Lecture notes in computer science; ISSN 0302-9743; Allemagne; Da. 2006; Vol. 4277; Pp. 648-657; Bibl. 17 ref. |
|---|
| LA : | Anglais |
|---|
| EA : | Pharmacogenomics studies the involvement of interindividual variations of DNA sequence in different drug responses (especially adverse drug reactions). Knowledge Discovery in Databases (KDD) process is a means for discovering new pharmacogenomic knowledge in biological databases. However data complexity makes it necessary to guide the KDD process by representation of domain knowledge. Three domains at least are in concern: genotype, drug and phenotype. The approach described here aims at reusing whenever possible existing domain knowledge in order to build a modular formal representation of domain knowledge in pharmacogenomics. The resulting ontology is called SO-Pharm for Suggested Ontology for Pharmacogenomics. Various situations encountered during the construction process are analyzed and discussed. A preliminary validation is provided by representing with SO-Pharm concepts some well-known examples of pharmacogenomic knowledge. |
|---|
| CC : | 001D02B07D; 002B02A; 001D02B07B; 001D02C |
|---|
| FD : | Système réparti; Internet; Ontologie; Découverte connaissance; Fouille donnée; Représentation connaissance; Construction modulaire; DNA; Médicament; Industrie pharmaceutique; Génotype; Base de connaissances; Phénotype; Validation; . |
|---|
| ED : | Distributed system; Internet; Ontology; Knowledge discovery; Data mining; Knowledge representation; Modular construction; DNA; Drug; Pharmaceutical industry; Genotype; Knowledge base; Phenotype; Validation |
|---|
| SD : | Sistema repartido; Internet; Ontología; Descubrimiento conocimiento; Busca dato; Representación conocimientos; Construcción modular; DNA; Medicamento; Industria farmacéutica; Genotipo; Base conocimiento; Fenotipo; Validación |
|---|
| LO : | INIST-16343.354000172814200850 |
|---|
| ID : | 08-0058235 |
|---|
Links to Exploration step
Pascal:08-0058235
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Suggested Ontology for Pharmacogenomics (SO-Pharm) : Modular Construction and Preliminary Testing</title>
<author><name sortKey="Coulet, Adrien" sort="Coulet, Adrien" uniqKey="Coulet A" first="Adrien" last="Coulet">Adrien Coulet</name>
<affiliation><inist:fA14 i1="01"><s1>KIKA Medical, 35 rue de Rambouillet</s1>
<s2>75012 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14><affiliation><inist:fA14 i1="02"><s1>LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239</s1>
<s2>54506 Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14><author><name sortKey="Smail Tabbone, Malika" sort="Smail Tabbone, Malika" uniqKey="Smail Tabbone M" first="Malika" last="Smail-Tabbone">Malika Smail-Tabbone</name>
<affiliation><inist:fA14 i1="02"><s1>LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239</s1>
<s2>54506 Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14><author><name sortKey="Napoli, Amedeo" sort="Napoli, Amedeo" uniqKey="Napoli A" first="Amedeo" last="Napoli">Amedeo Napoli</name>
<affiliation><inist:fA14 i1="02"><s1>LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239</s1>
<s2>54506 Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14><author><name sortKey="Devignes, Marie Dominique" sort="Devignes, Marie Dominique" uniqKey="Devignes M" first="Marie-Dominique" last="Devignes">Marie-Dominique Devignes</name>
<affiliation><inist:fA14 i1="02"><s1>LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239</s1>
<s2>54506 Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0058235</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 08-0058235 INIST</idno>
<idno type="RBID">Pascal:08-0058235</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000342</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Suggested Ontology for Pharmacogenomics (SO-Pharm) : Modular Construction and Preliminary Testing</title>
<author><name sortKey="Coulet, Adrien" sort="Coulet, Adrien" uniqKey="Coulet A" first="Adrien" last="Coulet">Adrien Coulet</name>
<affiliation><inist:fA14 i1="01"><s1>KIKA Medical, 35 rue de Rambouillet</s1>
<s2>75012 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14><affiliation><inist:fA14 i1="02"><s1>LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239</s1>
<s2>54506 Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14><author><name sortKey="Smail Tabbone, Malika" sort="Smail Tabbone, Malika" uniqKey="Smail Tabbone M" first="Malika" last="Smail-Tabbone">Malika Smail-Tabbone</name>
<affiliation><inist:fA14 i1="02"><s1>LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239</s1>
<s2>54506 Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14><author><name sortKey="Napoli, Amedeo" sort="Napoli, Amedeo" uniqKey="Napoli A" first="Amedeo" last="Napoli">Amedeo Napoli</name>
<affiliation><inist:fA14 i1="02"><s1>LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239</s1>
<s2>54506 Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14><author><name sortKey="Devignes, Marie Dominique" sort="Devignes, Marie Dominique" uniqKey="Devignes M" first="Marie-Dominique" last="Devignes">Marie-Dominique Devignes</name>
<affiliation><inist:fA14 i1="02"><s1>LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239</s1>
<s2>54506 Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14><series><title level="j" type="main">Lecture notes in computer science</title>
<idno type="ISSN">0302-9743</idno>
<imprint><date when="2006">2006</date>
</imprint><seriesStmt><title level="j" type="main">Lecture notes in computer science</title>
<idno type="ISSN">0302-9743</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DNA</term>
<term>Data mining</term>
<term>Distributed system</term>
<term>Drug</term>
<term>Genotype</term>
<term>Internet</term>
<term>Knowledge base</term>
<term>Knowledge discovery</term>
<term>Knowledge representation</term>
<term>Modular construction</term>
<term>Ontology</term>
<term>Pharmaceutical industry</term>
<term>Phenotype</term>
<term>Validation</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système réparti</term>
<term>Internet</term>
<term>Ontologie</term>
<term>Découverte connaissance</term>
<term>Fouille donnée</term>
<term>Représentation connaissance</term>
<term>Construction modulaire</term>
<term>DNA</term>
<term>Médicament</term>
<term>Industrie pharmaceutique</term>
<term>Génotype</term>
<term>Base de connaissances</term>
<term>Phénotype</term>
<term>Validation</term>
<term>.</term>
</keywords><front><div type="abstract" xml:lang="en">Pharmacogenomics studies the involvement of interindividual variations of DNA sequence in different drug responses (especially adverse drug reactions). Knowledge Discovery in Databases (KDD) process is a means for discovering new pharmacogenomic knowledge in biological databases. However data complexity makes it necessary to guide the KDD process by representation of domain knowledge. Three domains at least are in concern: genotype, drug and phenotype. The approach described here aims at reusing whenever possible existing domain knowledge in order to build a modular formal representation of domain knowledge in pharmacogenomics. The resulting ontology is called SO-Pharm for Suggested Ontology for Pharmacogenomics. Various situations encountered during the construction process are analyzed and discussed. A preliminary validation is provided by representing with SO-Pharm concepts some well-known examples of pharmacogenomic knowledge.</div>
</front><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0302-9743</s0>
</fA01><fA05><s2>4277</s2>
</fA05><fA08 i1="01" i2="1" l="ENG"><s1>Suggested Ontology for Pharmacogenomics (SO-Pharm) : Modular Construction and Preliminary Testing</s1>
</fA08><fA09 i1="01" i2="1" l="ENG"><s1>On the move to meaningful internet systems 2006. Part I-II : OTM 2006 workshops : OTM Confederated International Workshops and Posters, AWeSOMe, CAMS, COMINF, IS, KSinBIT, MIOS-CIAO, MONET, OnToContent, ORM, PerSys, OTM Academy Doctoral Consortium, RDDS, SWWS, and SeBGIS 2006, Montpellier, France, October 29 - November 3, 2006 : proceedings</s1>
</fA09><fA11 i1="01" i2="1"><s1>COULET (Adrien)</s1>
</fA11><fA11 i1="02" i2="1"><s1>SMAIL-TABBONE (Malika)</s1>
</fA11><fA11 i1="03" i2="1"><s1>NAPOLI (Amedeo)</s1>
</fA11><fA11 i1="04" i2="1"><s1>DEVIGNES (Marie-Dominique)</s1>
</fA11><fA14 i1="01"><s1>KIKA Medical, 35 rue de Rambouillet</s1>
<s2>75012 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14><fA14 i1="02"><s1>LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239</s1>
<s2>54506 Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14><fA20><s1>648-657</s1>
</fA20><fA21><s1>2006</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA26 i1="01"><s0>3-540-48269-5</s0>
</fA26><fA43 i1="01"><s1>INIST</s1>
<s2>16343</s2>
<s5>354000172814200850</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>17 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>08-0058235</s0>
</fA47><fA60><s1>P</s1>
<s2>C</s2>
</fA60><fA64 i1="01" i2="1"><s0>Lecture notes in computer science</s0>
</fA64><fA66 i1="01"><s0>DEU</s0>
</fA66><fA66 i1="02"><s0>USA</s0>
</fA66><fC01 i1="01" l="ENG"><s0>Pharmacogenomics studies the involvement of interindividual variations of DNA sequence in different drug responses (especially adverse drug reactions). Knowledge Discovery in Databases (KDD) process is a means for discovering new pharmacogenomic knowledge in biological databases. However data complexity makes it necessary to guide the KDD process by representation of domain knowledge. Three domains at least are in concern: genotype, drug and phenotype. The approach described here aims at reusing whenever possible existing domain knowledge in order to build a modular formal representation of domain knowledge in pharmacogenomics. The resulting ontology is called SO-Pharm for Suggested Ontology for Pharmacogenomics. Various situations encountered during the construction process are analyzed and discussed. A preliminary validation is provided by representing with SO-Pharm concepts some well-known examples of pharmacogenomic knowledge.</s0>
</fC01><fC02 i1="01" i2="X"><s0>001D02B07D</s0>
</fC02><fC02 i1="02" i2="X"><s0>002B02A</s0>
</fC02><fC02 i1="03" i2="X"><s0>001D02B07B</s0>
</fC02><fC02 i1="04" i2="X"><s0>001D02C</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système réparti</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Distributed system</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema repartido</s0>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Internet</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Internet</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Internet</s0>
<s5>02</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Ontologie</s0>
<s5>06</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Ontology</s0>
<s5>06</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Ontología</s0>
<s5>06</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Découverte connaissance</s0>
<s5>07</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Knowledge discovery</s0>
<s5>07</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Descubrimiento conocimiento</s0>
<s5>07</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Fouille donnée</s0>
<s5>08</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Data mining</s0>
<s5>08</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Busca dato</s0>
<s5>08</s5>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Représentation connaissance</s0>
<s5>09</s5>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Knowledge representation</s0>
<s5>09</s5>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Representación conocimientos</s0>
<s5>09</s5>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Construction modulaire</s0>
<s5>18</s5>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Modular construction</s0>
<s5>18</s5>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Construcción modular</s0>
<s5>18</s5>
</fC03><fC03 i1="08" i2="X" l="FRE"><s0>DNA</s0>
<s5>19</s5>
</fC03><fC03 i1="08" i2="X" l="ENG"><s0>DNA</s0>
<s5>19</s5>
</fC03><fC03 i1="08" i2="X" l="SPA"><s0>DNA</s0>
<s5>19</s5>
</fC03><fC03 i1="09" i2="X" l="FRE"><s0>Médicament</s0>
<s5>20</s5>
</fC03><fC03 i1="09" i2="X" l="ENG"><s0>Drug</s0>
<s5>20</s5>
</fC03><fC03 i1="09" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>20</s5>
</fC03><fC03 i1="10" i2="X" l="FRE"><s0>Industrie pharmaceutique</s0>
<s5>21</s5>
</fC03><fC03 i1="10" i2="X" l="ENG"><s0>Pharmaceutical industry</s0>
<s5>21</s5>
</fC03><fC03 i1="10" i2="X" l="SPA"><s0>Industria farmacéutica</s0>
<s5>21</s5>
</fC03><fC03 i1="11" i2="X" l="FRE"><s0>Génotype</s0>
<s5>22</s5>
</fC03><fC03 i1="11" i2="X" l="ENG"><s0>Genotype</s0>
<s5>22</s5>
</fC03><fC03 i1="11" i2="X" l="SPA"><s0>Genotipo</s0>
<s5>22</s5>
</fC03><fC03 i1="12" i2="X" l="FRE"><s0>Base de connaissances</s0>
<s5>23</s5>
</fC03><fC03 i1="12" i2="X" l="ENG"><s0>Knowledge base</s0>
<s5>23</s5>
</fC03><fC03 i1="12" i2="X" l="SPA"><s0>Base conocimiento</s0>
<s5>23</s5>
</fC03><fC03 i1="13" i2="X" l="FRE"><s0>Phénotype</s0>
<s5>24</s5>
</fC03><fC03 i1="13" i2="X" l="ENG"><s0>Phenotype</s0>
<s5>24</s5>
</fC03><fC03 i1="13" i2="X" l="SPA"><s0>Fenotipo</s0>
<s5>24</s5>
</fC03><fC03 i1="14" i2="X" l="FRE"><s0>Validation</s0>
<s5>25</s5>
</fC03><fC03 i1="14" i2="X" l="ENG"><s0>Validation</s0>
<s5>25</s5>
</fC03><fC03 i1="14" i2="X" l="SPA"><s0>Validación</s0>
<s5>25</s5>
</fC03><fC03 i1="15" i2="X" l="FRE"><s0>.</s0>
<s4>INC</s4>
<s5>82</s5>
</fC03><fN21><s1>028</s1>
</fN21><fN44 i1="01"><s1>OTO</s1>
</fN44><fN82><s1>OTO</s1>
</fN82><pR><fA30 i1="01" i2="1" l="ENG"><s1>OTM Confederated International Workshops</s1>
<s3>Montpellier FRA</s3>
<s4>2006</s4>
</fA30><server><NO>PASCAL 08-0058235 INIST</NO>
<ET>Suggested Ontology for Pharmacogenomics (SO-Pharm) : Modular Construction and Preliminary Testing</ET>
<AU>COULET (Adrien); SMAIL-TABBONE (Malika); NAPOLI (Amedeo); DEVIGNES (Marie-Dominique)</AU>
<AF>KIKA Medical, 35 rue de Rambouillet/75012 Paris/France (1 aut.); LORIA (UMR 7503 CNRS-INPL-INRIA-Nancy2-UHP), Campus scientifique, BP 239/54506 Vandoeuvre-lès-Nancy/France (1 aut., 2 aut., 3 aut., 4 aut.)</AF>
<DT>Publication en série; Congrès; Niveau analytique</DT>
<SO>Lecture notes in computer science; ISSN 0302-9743; Allemagne; Da. 2006; Vol. 4277; Pp. 648-657; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<EA>Pharmacogenomics studies the involvement of interindividual variations of DNA sequence in different drug responses (especially adverse drug reactions). Knowledge Discovery in Databases (KDD) process is a means for discovering new pharmacogenomic knowledge in biological databases. However data complexity makes it necessary to guide the KDD process by representation of domain knowledge. Three domains at least are in concern: genotype, drug and phenotype. The approach described here aims at reusing whenever possible existing domain knowledge in order to build a modular formal representation of domain knowledge in pharmacogenomics. The resulting ontology is called SO-Pharm for Suggested Ontology for Pharmacogenomics. Various situations encountered during the construction process are analyzed and discussed. A preliminary validation is provided by representing with SO-Pharm concepts some well-known examples of pharmacogenomic knowledge.</EA>
<CC>001D02B07D; 002B02A; 001D02B07B; 001D02C</CC>
<FD>Système réparti; Internet; Ontologie; Découverte connaissance; Fouille donnée; Représentation connaissance; Construction modulaire; DNA; Médicament; Industrie pharmaceutique; Génotype; Base de connaissances; Phénotype; Validation; .</FD>
<ED>Distributed system; Internet; Ontology; Knowledge discovery; Data mining; Knowledge representation; Modular construction; DNA; Drug; Pharmaceutical industry; Genotype; Knowledge base; Phenotype; Validation</ED>
<SD>Sistema repartido; Internet; Ontología; Descubrimiento conocimiento; Busca dato; Representación conocimientos; Construcción modular; DNA; Medicamento; Industria farmacéutica; Genotipo; Base conocimiento; Fenotipo; Validación</SD>
<LO>INIST-16343.354000172814200850</LO>
<ID>08-0058235</ID>
</server>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000342 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000342 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:08-0058235
|texte= Suggested Ontology for Pharmacogenomics (SO-Pharm) : Modular Construction and Preliminary Testing
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Mon Jun 10 21:56:28 2019. Site generation: Fri Feb 25 15:29:27 2022 |  |
